Form 4: Director Mark Buthman Receives WST Restricted Stock Units

West Pharmaceutical Services Director Mark A. Buthman acquired 791 restricted stock units as part of an equity grant.

Summary

• Director Mark A. Buthman was granted 791 restricted stock units (RSUs) of West Pharmaceutical Services, Inc. (WST).
• The transaction occurred on May 4, 2026, at a price of $0 per share, representing an equity compensation award.
• Following this transaction, the director's total beneficial ownership in the company increased to 44,308.5494 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of director compensation that does not signal a change in company strategy or financial health.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• None identified; this is a routine regulatory filing regarding director compensation.

Future Outlook

The restricted stock units are scheduled to vest in full on the date of the next annual shareholder meeting.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the pharmaceutical packaging and medical device industry to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The grant of restricted stock units to directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard director compensation.

Next Steps

• Vesting of the 791 restricted stock units upon the next annual shareholder meeting.

Key Dates

Keywords

West Pharmaceutical Services, WST, Form 4, Insider Trading, Director Compensation, Equity Grant